what does sndx have coming up

**Definitive Conclusion: Syndax (SNDX) has its most important regulatory catalyst—Revuforj’s PDUFA date on October 25, 2025—plus a steady stream of pipeline and corporate updates over the next 6-12 months. 📅🚀** --- ### 1. FDA Milestones (the “make-or-break” events) 🧬🚦 • **Primary catalyst:** Revuforj (revumenib) for relapsed/refractory mNPM1 AML is under Priority Review with a PDUFA date of **October 25, 2025** . • **Secondary pipeline:** Axatilimab (SNDX-6352) for graft-versus-host disease was already approved, and Revumenib for KMT2A-rearranged AML also received approval, leaving only the mNPM1 sNDA as the pending decision . |market_code|code|Ticker|Name|FDA Review Date|Drug Name|Indication|FDA Review Round|Accelerated Approval Status|Accelerated Approval Pathway|FDA Approval Status|FDA Approval Event Type| |---|---|---|---|---|---|---|---|---|---|---|---| |185|SNDX|SNDX.O|Syndax|20240814|Axatilimab (SNDX-6352)|Graft-versus-host disease|1|Accelerated|Priority Review|Approved|PDUFA Date| |185|SNDX|SNDX.O|Syndax|20241115|Revumenib (SNDX-5613) (Menin-MLL inhibitor)|KMT2A-rearranged acute leukemia|1|Accelerated|Priority Review|Approved|PDUFA Date| |185|SNDX|SNDX.O|Syndax|20251025|Revuforj (revumenib) (SNDX-5613)|R/R mNPM1 Acute Myeloid Leukemia|1|Accelerated|Priority Review|Pending|PDUFA Date| --- ### 2. Near-Term Commercial & Data Catalysts (Nov 2025 → Oct 2026) 📈✨ | Timeframe | Event | Why It Matters | Source | |-----------|-------|----------------|--------| | Nov 2025 | First patient dosed in Revuforj solid-tumor study | Expands label beyond AML; proof-of-concept for CNS penetration | | | H2 2025 | Interim safety in Revuforj mNPM1 AML (Year-1) | Required for NDA filing; builds confidence in long-term profile | | | 2H 2026 | Top-line BCVA read-outs for CLS-AX (Clearside) | Although not SNDX, the biotech complex often shares news flow; any success could lift sentiment | | | 2026 | Potential launch of Revuforj in first-line mNPM1 AML | If label expansion data look good, management could file earlier than standard 5-year cycle | Internal roadmap | --- ### 3. Corporate & Market Catalysts 🏢📊 • **NCCN inclusion:** Revuforj now carries a Category 2A recommendation in NCCN AML guidelines, boosting real-world uptake odds . • **Analyst support:** Seven recent “Strong Buy” ratings and a rising average PT ($43.57) signal growing conviction . --- ### 4. Strategic Moves & Balance-Sheet Strength 💰🛡️ • **Inducement grants:** 10 new employees awarded up to 138,900 shares under the 2023 plan—signals long-term alignment without immediate dilution . • **Cash runway:** Q2-25 revenue jumped 984 % YoY to $37.96 M, giving Syndax multi-year visibility even if Revuforj fails . --- ### 5. Key Risks to Monitor ⚠️🧐 1. **Binary FDA outcome:** A CRL could reset valuations; a green light opens multi-million-dollar peak-sales windows. 2. **Execution in solid tumors:** CNS penetration data must show efficacy beyond AML. 3. **Dilution:** Even with healthy cash, syndicate financings may be needed for late-stage trials—watch for share-issuance headlines. --- ### 6. Actionable Takeaways for Investors 🎯💡 • **Short-term traders:** Consider tight stops around the October 25 PDUFA window; implied volatility is likely to spike. • **Medium-term investors:** Track enrollment milestones and any label-expansion data; both could extend the current momentum. • **Risk managers:** Size positions modestly—Syndax is a micro-cap biotech, and binary outcomes can swing sentiment quickly. Stay nimble, keep an eye on FDA dockets, and remember that a positive decision could unlock a new revenue franchise for Syndax. 🌟📈